https://c4xdiscovery.com/half-year-results-for-the-six-months-ended-31-january-2021/2024-06-03T10:01:37+01:00https://c4xdiscovery.com/is-big-pharma-falling-back-in-love-with-small-molecules/2024-06-03T10:06:37+01:00https://c4xdiscovery.com/board-changes-c4x-discovery-appoints-simon-harford-as-non-executive-director/2024-06-03T10:01:28+01:00https://c4xdiscovery.com/c4x-discovery-announce-sizeable-deal-and-one-were-very-proud-of-with-sanofi-worth-up-to-e414mln/2024-06-03T09:58:31+01:00https://c4xdiscovery.com/sano-genetics-partners-with-benevolentai-c4x-discovery-to-power-precision-medicine-in-inflammatory-bowel-disease/2024-06-03T09:58:25+01:00https://c4xdiscovery.com/crystal-structures-of-tolfenamic-acid-polymorphic-forms-i-and-ii-with-precise-hydrogen-atom-positions-for-nuclear-magnetic-resonance-studies/2024-06-03T09:57:26+01:00https://c4xdiscovery.com/up-to-e414-million-exclusive-worldwide-licensing-agreement-with-sanofi-for-c4xd-oral-il-17a-inhibitor-programme/2024-06-03T10:01:24+01:00https://c4xdiscovery.com/results-of-agm/2024-06-03T09:58:14+01:00https://c4xdiscovery.com/publication-of-2020-annual-report/2024-06-03T09:58:09+01:00https://c4xdiscovery.com/full-year-results/2024-06-03T09:58:00+01:00https://c4xdiscovery.com/clive-dix-named-interim-chair-of-vaccine-taskforce/2024-06-03T09:57:55+01:00https://c4xdiscovery.com/result-of-general-meeting-and-issue-of-equity/2024-06-03T09:57:50+01:00https://c4xdiscovery.com/result-of-placing/2024-06-03T09:57:33+01:00https://c4xdiscovery.com/proposed-placing-to-raise-approximately-15-0-million/2024-06-03T09:57:38+01:00https://c4xdiscovery.com/business-update/2024-06-03T09:57:21+01:00https://c4xdiscovery.com/result-of-agm/2024-06-03T09:58:18+01:00https://c4xdiscovery.com/full-year-results-2/2024-06-03T10:08:11+01:00https://c4xdiscovery.com/c4x-discovery-holdings-says-four-programs-in-great-shape-to-start-finding-right-partner-for-each/2024-06-03T09:58:04+01:00https://c4xdiscovery.com/c4x-discovery-makes-significant-progress-hails-start-of-indivior-trial-joins-coronavirus-initiative/2024-06-03T09:57:15+01:00https://c4xdiscovery.com/the-promise-of-drug-discovery/2024-06-03T09:57:10+01:00https://c4xdiscovery.com/momentum-building-within-c4x-discovery-portfolio-as-it-looks-to-license-nrf-2-programme/2024-04-26T10:46:17+01:00https://c4xdiscovery.com/board-change/2024-06-03T10:01:42+01:00https://c4xdiscovery.com/c4x-discovery-ceo-clive-dix-receives-obn-special-recognition-award-2021/2024-06-03T10:01:48+01:00https://c4xdiscovery.com/clive-dix-awarded-honorary-fellowship/2024-06-03T10:01:53+01:00https://c4xdiscovery.com/board-change-2/2024-06-03T10:01:59+01:00https://c4xdiscovery.com/lifetime-achievement-award/2024-06-03T10:02:04+01:00https://c4xdiscovery.com/full-year-results-3/2024-06-03T10:02:13+01:00https://c4xdiscovery.com/c4x-discovery-holdings-highlight-their-good-position-for-advancement-and-expansion-in-current-year/2024-06-03T10:02:19+01:00https://c4xdiscovery.com/posting-of-2021-annual-report-and-notice-of-agm/2024-06-03T10:02:28+01:00https://c4xdiscovery.com/dr-catherine-tralau-stewart-appointed-as-c4xds-chief-scientific-officer/2024-06-03T10:02:33+01:00https://c4xdiscovery.com/result-of-agm-3/2024-06-03T10:02:38+01:00https://c4xdiscovery.com/bhavna-hunjan-appointed-to-the-board-as-chief-business-officer/2024-06-03T10:02:44+01:00https://c4xdiscovery.com/introducing-cathy-tralau-stewart/2024-06-03T10:02:51+01:00https://c4xdiscovery.com/copd-lung-studies-of-nrf2-expression-and-the-effects-of-nrf2-activators/2024-06-03T10:02:56+01:00https://c4xdiscovery.com/half-year-results-2022-2/2024-06-03T10:03:01+01:00https://c4xdiscovery.com/expanding-its-portfolio/2024-06-03T10:03:06+01:00https://c4xdiscovery.com/clive-dix-appointed-to-the-board-of-precision-health-technologies-accelerator/2024-06-03T10:03:11+01:00https://c4xdiscovery.com/sdpd-sx-combining-a-single-crystal-x-ray-diffraction-setup-with-advanced-powder-data-structure-determination-for-use-in-early-stage-drug-discovery/2024-06-03T10:03:16+01:00https://c4xdiscovery.com/c4x-discovery-receives-first-milestone-payment-from-sanofi/2024-06-03T10:03:21+01:00https://c4xdiscovery.com/bhavna-hunjan-wins-a-rising-star-award-for-movers-and-shakers-in-biobusiness-2017/2024-06-03T10:03:35+01:00https://c4xdiscovery.com/revenue-generating-progress-for-partnered-programmes-with-continued-momentum-across-drug-discovery-portfolio/2024-06-03T10:05:13+01:00https://c4xdiscovery.com/c4xd-and-hitgen-to-collaborate-in-inflammation-hit-identification-project/2024-04-26T10:13:57+01:00https://c4xdiscovery.com/c4xd-signs-exclusive-global-licence-worth-up-to-402-million1-with-astrazeneca-for-the-development-and-commercialisation-of-nrf2-activator-programme-2/2024-06-03T09:55:54+01:00https://c4xdiscovery.com/full-year-results-15-12-2022/2024-06-03T09:55:41+01:00https://c4xdiscovery.com/c4xd-appoints-nick-ray-as-chief-scientific-officer/2024-06-03T09:55:35+01:00https://c4xdiscovery.com/malt-1-inhibitor-programme-update/2024-06-03T09:55:29+01:00https://c4xdiscovery.com/c4xd-and-garvan-institute-of-medical-research-report-successful-patient-stratification-approach-using-c4xds-new-precision-medicine-platform-patientseek/2024-06-03T09:55:06+01:00https://c4xdiscovery.com/half-year-results-for-the-six-months-ended-31-january-2023/2024-06-03T09:54:43+01:00https://c4xdiscovery.com/proactive-investor-to-discuss-c4xds-interims/2024-06-03T09:54:38+01:00https://c4xdiscovery.com/international-clinical-trials-features-c4xd/2024-06-03T09:54:28+01:00https://c4xdiscovery.com/board-change-june-2023/2024-06-03T09:54:22+01:00https://c4xdiscovery.com/strategic-divestment-of-c4xds-orexin-1-receptor-antagonist-programme-to-indivior-for-15-95-million/2024-06-03T09:54:16+01:00https://c4xdiscovery.com/full-year-results-2023/2024-06-03T09:54:02+01:00https://c4xdiscovery.com/posting-of-2023-annual-report-and-notice-of-agm/2024-06-03T09:53:57+01:00https://c4xdiscovery.com/astrazeneca-triggers-11-million-preclinical-milestone-payment-to-c4x-discovery-under-its-nrf2-exclusive-worldwide-licence-agreement-worth-up-to-402-million/2024-06-03T09:53:52+01:00https://c4xdiscovery.com/clive-dix-ceo-speaks-to-alex-ralph-on-the-receipt-of-11-million-milestone-payment-from-astrazeneca-following-progress-in-its-nrf2-activer-programme/2024-06-03T09:53:37+01:00https://c4xdiscovery.com/c4xd-signs-exclusive-global-licence-worth-up-to-402-million1-with-astrazeneca-for-the-development-and-commercialisation-of-nrf2-activator-programme/2024-06-03T09:56:04+01:00https://c4xdiscovery.com/result-of-agm-4/2024-06-03T09:53:24+01:00https://c4xdiscovery.com/polymorph-identification-for-flexible-molecules/2024-06-03T09:52:44+01:00https://c4xdiscovery.com/a-novel-non-opioid-selective-orexin-1-receptor-antagonist-for-the-treatment-of-substance-use-disorders/2024-06-03T09:52:50+01:00https://c4xdiscovery.com/half-year-results-for-the-six-months-ended-31-january-2024/2024-06-03T09:53:15+01:00https://c4xdiscovery.com/proposed-voluntary-cancellation-of-admission-of-ordinary-shares-to-trading-on-aim/2024-06-03T09:53:09+01:00https://c4xdiscovery.com/vernalis-announces-a-drug-discovery-collaboration-with-c4x-discovery-in-inflammatory-disease/2024-06-03T09:53:04+01:00https://c4xdiscovery.com/malt-1-inhibitor-programme-update-june-2023/2024-06-03T09:54:33+01:00https://c4xdiscovery.com/board-change-mario-polywka/2024-06-03T09:53:32+01:00https://c4xdiscovery.com/result-of-general-meeting-15-april-2024/2024-06-03T09:52:59+01:00https://c4xdiscovery.com/last-day-of-dealings-and-update-on-cancellation/2024-04-26T00:37:56+01:00https://c4xdiscovery.com/unveiling-new-genetic-insights-in-rheumatoid-arthritis-for-drug-discovery-through-taxonomy3-analysis/2024-07-04T10:35:40+01:00https://c4xdiscovery.com/c4xd-announces-progress-on-immuno-inflammation-programmes-andappointment-of-new-board-members/2024-07-24T13:31:29+01:00https://c4xdiscovery.com/chemical-modification-of-hyaluronan-oligosaccharides-differentially-modulates-hyaluronan-hyaladherin-interactions/2024-08-29T09:13:38+01:00https://c4xdiscovery.com/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder-and-non-responder-populations-in-inflammatory-bowel-disease/2024-09-14T16:31:19+01:00https://c4xdiscovery.com/ceo-clive-dix-joins-in-vivos-ashley-yeo-to-discuss-c4xds-recent-success-with-its-patientseek-platform-which-has-identified-genetic-signatures-that-predict-patient-response-to-vedoliz/2024-10-07T16:19:49+01:00https://c4xdiscovery.com/board-change-david-lawrence-appointed-as-interim-chairman-clive-dix-to-retire-from-leading-the-company/2025-01-02T16:28:25+00:00https://c4xdiscovery.com/c4x-discovery-receives-latest-milestone-payment-from-sanofi/2025-05-27T07:30:19+01:00https://c4xdiscovery.com/c4x-discovery-announces-selection-of-a-once-daily-development-candidate-from-its-a4b7-inhibitor-programme/2025-09-22T07:31:34+01:00https://c4xdiscovery.com/written-resolutions-result/2026-06-26T13:04:06+01:00